{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:06:36Z","timestamp":1788941196365,"version":"build-2803163510"},"reference-count":11,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    This post hoc analysis examined the impact of prior immunosuppressants on the long\u2010term efficacy and safety of inebilizumab, a cluster of differentiation 19\n                    <jats:sup>+<\/jats:sup>\n                    B\u2010cell\u2013depleting monoclonal antibody, in participants with aquaporin\u20104\u2013seropositive neuromyelitis optica spectrum disorder from the N\u2010MOmentum trial (NTC02200770). Inebilizumab treatment resulted in a sustained low annualized attack rate relative to the pretrial annualized attack rate and a high probability of remaining attack\u2010free for up to 4\u2009years among participants with and without prior immunosuppressant use. Based on modeling data, inebilizumab had greater long\u2010term efficacy than historical immunosuppressants. Inebilizumab was well tolerated regardless of prior immunosuppressant use.\n                  <\/jats:p>","DOI":"10.1002\/acn3.70426","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:43:29Z","timestamp":1778579009000},"page":"1930-1936","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Inebilizumab in N\u2010\n                    <scp>MOmentum<\/scp>\n                    Trial Participants With or Without Prior Immunosuppressants"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-2533","authenticated-orcid":false,"given":"Bruce A. C.","family":"Cree","sequence":"first","affiliation":[{"name":"UCSF Weill Institute for Neurosciences, Department of Neurology University of California San Francisco  California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Suero","sequence":"additional","affiliation":[{"name":"Eversana  Burlington Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Walsh","sequence":"additional","affiliation":[{"name":"Eversana  Burlington Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5967-2800","authenticated-orcid":false,"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[{"name":"Service de Neurologie, Scl\u00e9rose en Plaques, Pathologies de la My\u00e9line et Neuroinflammation H\u00f4pital Neurologique Pierre Wertheimer, Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Lindsey","sequence":"additional","affiliation":[{"name":"Division of Multiple Sclerosis and Neuroimmunology University of Texas Health Science Center at Houston  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-8419","authenticated-orcid":false,"given":"Ho Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology Research Institute and Hospital of National Cancer Center  Goyang Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewei","family":"She","sequence":"additional","affiliation":[{"name":"Amgen Inc.  California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cimbora","sequence":"additional","affiliation":[{"name":"Amgen Inc.  California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Cavida","sequence":"additional","affiliation":[{"name":"Amgen Inc.  California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6378-0070","authenticated-orcid":false,"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Research Center Max Delbrueck Center for Molecular Medicine and Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t Zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904655"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104718"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251314020"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30070-3"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084154"},{"key":"e_1_2_10_7_1","unstructured":"Amgen Inc. \u201cUPLIZNA (Inebilizumab\u2010Cdon) US Prescribing Information \u201d(2025) https:\/\/www.pi.amgen.com\/\u2010\/media\/Project\/Amgen\/Repository\/pi\u2010amgen\u2010com\/uplizna\/uplizna_fpi_english.pdf."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00077-2"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2145879"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11910-z"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200124"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70426","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acn3.70426","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:22:45Z","timestamp":1788938565000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.70426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/acn3.70426"],"URL":"https:\/\/doi.org\/10.1002\/acn3.70426","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"2025-12-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}